Glaucoma, Open-Angle Clinical Trial
Official title:
Evaluation of Choroidal Thickness Using Spectral Optical Coherence Tomography in Pseudoexfoliation Glaucoma and Primary Open Angle Glaucoma
Purpose: To investigate the effect of pseudoexfoliation (PEX) on choroidal thickness in
primary open-angle glaucoma (POAG).
Methods: This prospective, randomized study included 30 POAG patients and 30 PEX glaucoma
patients with similar demographic characteristics, and 30 eyes of 30 healthy individuals
comprised the control group. Macular choroidal thickness was measured using a Cirrus HD
spectral domain optical coherence tomography (OCT) instrument.
In the present study, the investigators aimed to evaluate the effect of the presence of PEX
on choroidal thickness in two groups of glaucoma patients with similar degrees of damage and
similar demographical characteristics. The investigators also evaluated whether there was a
correlation between choroidal thickness and indicators of glaucoma severity, such as retinal
nerve fiber layer (RNFL) thickness and mean deviation (MD) value, in these two glaucoma
types.
MATERIALS AND METHODS The study included 30 eyes of 30 patients diagnosed with POAG and 30
eyes of 30 patients diagnosed with PEX glaucoma who presented to Glaucoma Unit of Izmir Katip
Celebi University Atatürk Training and Research Hospital between August 2014 and February
2015. The control group included 30 eyes of 30 healthy individuals with similar age
distribution.
Approval was obtained from the ethics committee of Izmir Katip Celebi University Medical
School Atatürk Training and Research Hospital. Detailed informed consent forms were obtained
from each of the patients included in the study.
The study included subjects over 18 years old who had best corrected visual acuity of 0.5 or
better, transparent optic medium, at least two reliable visual field tests, and reliable
spectral domain (SD)-OCT (signal strength≥7/10) and EDI-OCT images (signal strength≥6/10)
Information pertaining to patients' systemic diseases and chronic medication use was
recorded. Patients with diabetes mellitus, systemic arterial hypertension, renal failure,
hemodialysis history, chronic medication, or smoking habit were not included.
Patients with retinal and neuro-ophthalmological diseases, amblyopia, active or previous
uveitis, previous ocular trauma, intraocular surgery within last 6 months, previous
trabeculectomy, or refractive error with a spherical equivalent greater than ±3.0 D were
excluded from the study. In order to minimize the effect of IOP on choroidal thickness,
patients with IOP higher than 21 mmHg at the time of OCT image acquisition were not included
in the study.
POAG was diagnosed based on high IOP (>21 mmHg) at the time of diagnosis, typical
glaucomatous optic disc and visual field changes, and normal anterior chamber angle. In
contrast, PEX glaucoma diagnosis was based on high IOP (>21 mmHg) at diagnosis and typical
glaucomatous optic disc and visual field changes, plus the presence of PEX material or
hyperpigmentation in the anterior chamber angle and the presence of PEX material at the
pupillary margins or the anterior lens on anterior segment examination after pupil dilation.
The control group consisted of healthy individuals with normal anterior and posterior segment
findings and IOP less than 21 mmHg.
All subjects underwent a detailed ophthalmologic examination. Axial length was measured using
IOL Master (Carl Zeiss Meditec, Dublin, CA, USA) optic biometry. Visual field was assessed
with Humphrey II Perimetry (Carl Zeiss Meditec, Dublin, CA, USA) SITA standard central 24-2
test. Tests with fixation loss less than 20%, false negative, and false positive response
rates below 33% were considered reliable. Patients with at least two reliable visual field
tests were included in the study. MD values were obtained.
Optic disc images were obtained with Cirrus 4000 HD-OCT (Carl ZeissMeditec, Dublin, CA, USA)
SD-OCT device. Mean RNFL thickness and vertical cup-to-disc (c/d) ratios were noted.
Choroidal imaging was done after pupil dilation using the EDI-OCT mode. The SD Cirrus HD-OCT
light source was centered on 800 nm wavelength to achieve 5 μm maximal resolution in tissue.
In order to minimize the effect of diurnal choroidal thickness variation on the measurements,
choroidal thickness measurements of all patients were made between 09:00 and 11:00 am, after
a resting period of 30 minutes. The macular field was scanned in the horizontal plane in
high-resolution 1 line raster mode. Patients were asked to focus on the instrument's internal
fixation light until the retinal image was acquired. Images with signal strength of 6/10 or
better were eligible for assessment. Patients who had at least two reliable high-resolution
foveal and choroidal imagings were included in the study.
The fovea centralis was determined by identifying the point of maximum depression in the
central 500-micron-diameter area. The internal and external choroidal margins were determined
manually in the section passing through the fovea centralis. These margins were drawn based
on criteria defined by Boonarpha et al.[15]. The posterior edge of the hyperreflective band
corresponding to the retinal pigment epithelium-Bruch's membrane complex was determined as
the anterior border of the choriocapillaris. The posterior border of the choriocapillaris was
demarcated as the hyperreflective band corresponding to the sclerochoroidal interface or the
hyporeflective line corresponding to suprachoroidal space. In cases where these two anatomic
structures could not be visualized, measurement was done using the prominent straight line
corresponding to the posterior margin of the large choroidal vessels. Patients in whom
choroidal margins could not be clearly distinguished were not included in the study.
High-resolution retinal choroidal images with distinct choroidal margins were transferred to
ImageJ software [40]. The high-resolution EDI-OCT images were 6000 microns wide and 2000
microns high, as indicated in the manufacturer's user's manual. EDI-OCT images to be measured
were opened using ImageJ software. The Scale command was selected in the Image tab of ImageJ
software menu. Using the Scale menu, width (pixels) was defined as 6000 and height (pixels)
as 2000. The distance to be measured was marked on the new image of 6000x2000 pixels and
measurements were done using the Measure command in Analyze tab. The choroidal margins were
drawn in this software according to the specified criteria, followed by manual measurements.
Measurements were taken vertically at the fovea centralis and in the nasal and temporal
quadrants at distances of 1500 and 2500 microns from the fovea centralis. The same researcher
repeated the measurements at different times using the double-blind method, and intraobserver
and intervisit measurement repeatability was assessed.
All data were analysed using SPSS software. Independent t-test was used to compare the
groups. The correlation between choroidal thickness and other variables (age, axial length,
vertical c/d, RNFL thickness, MD) was evaluated using Pearson correlation
analysis.Repeatability analysis of study parameters measured with Cirrus 4000 HD OCT was
evaluated using the coefficient of variation (CV). For CV calculation of choroidal thickness
measured by Cirrus 4000 HD OCT, 10 consequential measurements were obtained by the same
operator to the same eye of the subject. CV is defined as the ratio of the standard deviation
to the mean: cV=σ/μ
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05044793 -
A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System
|
||
Recruiting |
NCT06201455 -
Evaluation of Phacogoniotomy in Medically-controlled POAG
|
N/A | |
Recruiting |
NCT03369886 -
The Relationship Between Macular OCTA and GCIPL and Their Combinational Index Using AI
|
N/A | |
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Recruiting |
NCT02679482 -
Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma
|
N/A | |
Completed |
NCT02338362 -
Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma
|
Phase 4 | |
Active, not recruiting |
NCT01430923 -
Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost
|
N/A | |
Completed |
NCT01489670 -
Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
|
N/A | |
Completed |
NCT00693485 -
Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
|
Phase 2 | |
Completed |
NCT00753168 -
Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma
|
Phase 1/Phase 2 | |
Completed |
NCT00051194 -
A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension
|
Phase 2 | |
Recruiting |
NCT04920227 -
Comparation of CLASS Combined With Phacoemulsification and CLASS Alone in the Treatment of Primary Open Angle Glaucoma
|
N/A | |
Active, not recruiting |
NCT03868124 -
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
|
Phase 3 | |
Completed |
NCT03267862 -
Scleral Response to Intraocular Pressure (IOP)
|
N/A | |
Recruiting |
NCT06066645 -
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
|
Phase 3 | |
Recruiting |
NCT04912362 -
The Effectiveness of YAG Iridotomy in Preventing Peripheral Anterior Synechia After CLASS in Primary Open Angle Glaucoma
|
N/A | |
Completed |
NCT04949802 -
Glaucoma Surgery Using the ViaLase Laser System
|
N/A | |
Recruiting |
NCT04038034 -
Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma
|
N/A | |
Completed |
NCT04632329 -
Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma
|
N/A | |
Completed |
NCT01215786 -
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
|
Phase 1 |